BridgeBio Pharma, Inc. NMS · BBIO

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

GlobeNewswire Inc. · 11d ago

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

The Motley Fool · 16d ago

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

GlobeNewswire Inc. · 17d ago

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

Benzinga · 67d ago

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

GlobeNewswire Inc. · 110d ago

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

GlobeNewswire Inc. · 129d ago

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

Benzinga · 130d ago

Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio?

Benzinga · 146d ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 151d ago

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

Benzinga · 156d ago

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Benzinga · 199d ago

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

GlobeNewswire Inc. · 252d ago

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

GlobeNewswire Inc. · 253d ago

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

GlobeNewswire Inc. · 264d ago

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

GlobeNewswire Inc. · 293d ago

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

GlobeNewswire Inc. · 315d ago

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

GlobeNewswire Inc. · 322d ago

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Benzinga · 346d ago

KRAS Inhibitors Market Size Clinical Trials Patent Approved Drugs Sales Insight

GlobeNewswire Inc. · 374d ago

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Benzinga · 442d ago

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

GlobeNewswire Inc. · 446d ago

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?

The Motley Fool · 459d ago

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

GlobeNewswire Inc. · 507d ago

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight

GlobeNewswire Inc. · 555d ago

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

GlobeNewswire Inc. · 602d ago